PFE - Allogene Therapeutics: Stay On The Sidelines On This Until 2020
Company Overview
Allogene Therapeutics (ALLO) is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (“AlloCAR T”) therapies for cancer. Allogene believes that the next revolution in cancer treatment is the development of AlloCAR T therapies engineered from the T cells of healthy donors.
Allogene was founded in April 2018 when it entered into an agreement to acquire Pfizer's (PFE) allogenic CAR-T portfolio whom they licensed from Servier and Cellectis (CLLS). In exchange, Pfizer received a 25 percent ownership stake in Allogene. At the same time,